A novel polymorphism of the gene encoding furin, a TGF-beta1 activator, and the influence on cardiac allograft vasculopathy formation

Transplant Immunology
C G DensemI V Hutchinson

Abstract

Coronary vasculopathy (CV) is an important determinant of survival following cardiac transplantation. We have previously shown that G915C polymorphism of the Transforming Growth Factor-beta1 (TGF-beta1) gene strongly influences CV development. Furin is a proprotein convertase enzyme important in TGF-beta1 activation. We investigated for polymorphism within the promoter region of the gene for furin (fur). Allelic variation of the fur gene, in conjunction with TGF-beta1 polymorphism, was subsequently related to the development of CV. The fur gene promoter region (position -1199 to +39) was analysed by SSCP and sequencing. A C/T single nucleotide substitution polymorphism at position -231* was identified. Using PCR the fur and TGFB1 genotypes were identified in 115 cardiac transplant recipients. CV was diagnosed at routine surveillance post-transplant coronary angiography. Fur polymorphism had no influence on vasculopathy development; median time to diagnosis, *C/C homozygotes, 2.27 years (2.10-4.32), *C/T heterozygotes 2.97 years (2.09-4.24), *T/T homozygotes 2.65 years (2.33-4.08), (P=0.95). Allelic variation did not influence Kaplan Meier actuarial analysis of disease onset (P=0.54). Ninety-three percent of recipients were high...Continue Reading

References

Oct 1, 1992·The Journal of Clinical Investigation·S NikolL Weir
Jan 1, 1992·DNA Sequence : the Journal of DNA Sequencing and Mapping·A Rosenthal, D S Charnock-Jones
Sep 1, 1991·The Journal of Clinical Investigation·M W MajeskyM A Reidy
Feb 1, 1991·Journal of the American College of Cardiology·D E JohnsonM Billingham
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A B RobertsJ H Kehrl
Dec 1, 1987·The Journal of Clinical Investigation·J A SchalkenW J Van de Ven
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·S M WahlM B Sporn
Apr 10, 1995·FEBS Letters·J B DenaultR Leduc
Mar 1, 1994·The Journal of Clinical Investigation·Y G WolfE Ruoslahti
Jan 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A B KulkarniS Karlsson
Apr 15, 1997·The Journal of Clinical Investigation·F BlanchetteC M Dubois
Oct 6, 1997·Transplantation·D TurnerI V Hutchinson
Jun 26, 1998·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·A El-GamelI V Hutchinson
Jul 20, 1999·Kidney International·D SankaranI V Hutchinson
Oct 21, 1999·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·A El-GamelI V Hutchinson
Mar 25, 2000·The Journal of Thoracic and Cardiovascular Surgery·T AzizI V Hutchinson
Jun 27, 2000·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·C G DensemN H Brooks
Jan 6, 2001·The American Journal of Pathology·C M DuboisN G Seidah
May 23, 2001·Arteriosclerosis, Thrombosis, and Vascular Biology·M NegishiT Takeuchi
Jun 26, 2001·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·T AzizI V Hutchinson

❮ Previous
Next ❯

Citations

Apr 18, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·M C HagemeijerR A de Weger
Jun 6, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rui Xiang LeiGui Hua Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.